Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Consensus Price Target from Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.3333.

AUTL has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Friday, December 12th. Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Finally, William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Marex Group plc acquired a new position in Autolus Therapeutics during the second quarter worth about $28,000. R Squared Ltd bought a new position in shares of Autolus Therapeutics in the second quarter valued at $50,000. Delaney Dennis R bought a new stake in shares of Autolus Therapeutics during the 2nd quarter worth $55,000. Forefront Wealth Management Inc. acquired a new position in shares of Autolus Therapeutics in the 2nd quarter worth $61,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Autolus Therapeutics during the third quarter worth $46,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Trading Down 4.6%

Shares of NASDAQ AUTL opened at $1.65 on Friday. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $2.80. The company has a market cap of $439.13 million, a PE ratio of -1.99 and a beta of 2.01. The stock has a 50 day simple moving average of $1.48 and a 200-day simple moving average of $1.79.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The business had revenue of $21.19 million during the quarter, compared to analyst estimates of $21.08 million. Sell-side analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.